Rubedo

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023

Retrieved on: 
Wednesday, May 3, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Tissue, Drug discovery, Pathology, Histopathology, Atopic dermatitis, Multimedia, Inflammation, RNA, Dermatitis, Psoriasis, Dermatology, Standard of care, Patient, Machine learning, LSX, Rubedo, SVP, IND, Conference, Skin, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230503005464/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230503005464/en/
    Marco Quarta, Ph.D., CEO & Co-Founder, Rubedo Life Sciences presenting at LSX World Conference 2023.
  • (Photo: Business Wire)
    RLS-1496 is a disease-modifying therapy with the potential for superiority over standard of care in multiple chronic skin indications.
  • Rubedo’s R&D program in dermatology was initiated in Q4 2021, and effective progression from target discovery to candidate nomination took one and a half years.
  • ALEMBIC™ Senescence Signatures were utilized to analyze skin samples derived from patients with chronic dermatological conditions, such as dermatitis and psoriasis.

Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases

Retrieved on: 
Monday, March 20, 2023
Research, Other Health, Pharmaceutical, Oncology, Consumer, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Seniors, Health, Other Science, Senior, Drug discovery, Department of Medicine – University of Pamplona, Histopathology, Ageing, Coronavirus Scientific Advisory Board, American Academy, Multimedia, Dermatitis, Cell, Inflammation, Psoriasis, Hair, Dermatology, Professor, Physician, AAD, Memorial Sloan Kettering Cancer Center, Rubedo, Pharmaceutical industry, Management, Vaccine

Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.

Key Points: 
  • Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.
  • The focus of the annual conference is to help dermatological professionals learn about the latest industry updates and research.
  • View the full release here: https://www.businesswire.com/news/home/20230320005208/en/
    Ofir Moreno, Ph.D., is Senior Vice President, Drug Discovery at Rubedo, presenting at the OncoDermatology Society conference.
  • Leveraging its proprietary single-cell multiomics platform ALEMBIC™, Rubedo identifies pathologic cells with senescence features characteristic of multiple dermatological chronic skin conditions, and is developing potent and selective compounds targeting those cells using its selective senolytic platform SenTech™.

Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program

Retrieved on: 
Monday, February 6, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Alembic, California Institute for Regenerative Medicine, Trial of the century, Climate change, Regenerative medicine, SARS-CoV-2, Therapy, Tissue, Pulmonary fibrosis, CIRM, Patient, Lung, Ageing, IPF, Survivor, Prodrug, Rubedo, Disease, Chemistry, Idiopathic pulmonary fibrosis, Air pollution, Quality of life, COVID-19, Drug discovery, Cellular senescence, Doctor of Philosophy, Pharmaceutical industry, Cedars-Sinai Medical Center, Medicine

This funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF) targeting senescent lung stem cells.

Key Points: 
  • This funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF) targeting senescent lung stem cells.
  • The goal is to develop a clinical study of the lead senolytic compound on the humanized IPF model.
  • Progressive pulmonary fibrosis is an age-related degenerative interstitial lung disease that affects an increasing number of individuals globally.
  • Cory Hogaboam, PhD, professor of Medicine at Cedars-Sinai, is leading the research for Cedars-Sinai that is supported by a grant from the California Institute for Regenerative Medicine (CIRM).

HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer

Retrieved on: 
Thursday, August 25, 2022
Johns Hopkins University, Partnership, Patient, University, CEO, Jim, Degenerative disease, Lists of diseases, Therapy, BS, Doctor of Philosophy, MMA, Disease, Propionic acidemia, MIT, Chemistry, Multimedia, Harvard University, Liver disease, BA, Retirement, Rhodes College, Leadership, Biology, Company, Biotechnology, NASH, Spring Arbor University, Horizon, Merck & Co., Biochemistry, Drug discovery, Fatty liver disease, Gout, Broad Institute, Drug development, Industry, Growth, Horizon Therapeutics, Pharmaceutical industry, Typesetting, Management, Rubedo, Takeda, Fulcrum

CHARLOTTESVILLE, Va., Aug. 25, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff, PhD, as interim chief executive officer. Dr. Wamhoff is a founder of HemoShear where he co-developed HemoShear's REVEAL-Tx™ drug discovery platform, which combines biological and computational models of human diseases to accelerate drug development. He has led the company's drug discovery programs in rare metabolic diseases and has forged successful drug discovery partnerships with Takeda and Horizon. Most recently he led the company's development of HST5040, a small molecule in a phase 2 clinical trial for the rare metabolic diseases methylmalonic acidemia (MMA) and propionic acidemia (PA). Dr. Wamhoff succeeds Jim Powers who is retiring after 14 years as CEO and chairman of HemoShear.

Key Points: 
  • CHARLOTTESVILLE, Va., Aug. 25, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare diseases, today announced the appointment of Brian Wamhoff, PhD, as interim chief executive officer.
  • Dr. Wamhoff succeeds Jim Powers who is retiring after 14 years as CEO and chairman of HemoShear.
  • Dr. Wamhoff, selected as one of the PharmaVOICE 100 most inspiring people in the industry in 2021, served as head of innovation and chief operating officer of HemoShear before being appointed as interim CEO.
  • HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need.

Rubedo Life Sciences Expands Leadership Team with Ali Siam as Chief Business Officer and Ofir Moreno, Ph.D., as SVP of Drug Discovery

Retrieved on: 
Monday, August 1, 2022
Biotechnology, Other Health, Health, Seniors, Pharmaceutical, Other Science, Research, Genetics, Consumer, Science, Clinical Trials, CA, Alembic, Infection, R, Bayer, Population, Biology, L.E.K. Consulting, Johnson & Johnson, Drug discovery, Dendreon, Neurodegeneration, Mechanical engineering, Prodrug, BS, CNS, Amgen, Multimedia, Marketing, Cellular senescence, Cell, AbbVie, Cell Chemical Biology, Merck, Boston Scientific, MBA, Ageing, Technology, Drug development, Senior, Mechanical, Patient, Metabolism, MEI, CBO, Growth, Cornell University, Pharmacy, Harvard University, List of life sciences, Pharmaceutical industry, Management, Chemistry, Rubedo, Neuroscience, Oncology, Immunology, Boston College, Northeastern University

View the full release here: https://www.businesswire.com/news/home/20220801005060/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220801005060/en/
    We are pleased to welcome Ali and Ofir, who bring invaluable experience and insights to our leadership team for this next stage of growth, said Marco Quarta, Ph.D., Chief Executive Officer and Co-Founder of Rubedo Life Sciences.
  • Im excited to join Rubedo at this important stage, as we advance our pipeline of potential best-in-class candidates targeting chronic age-related diseases, said Ali Siam, Chief Business Officer, Rubedo.
  • The team has developed a state-of-the-art computational platform to target senescent cells, said Ofir Moreno, Ph.D., Senior Vice President, Drug Discovery.
  • Ali Siam is Chief Business Officer (CBO) at Rubedo, where he leads business development and corporate strategy.